Intellia Therapeutics Inc

+0.24 (+0.38%)
4:50:56 PM EDT: $63.01 -0.55 (-0.87%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)4.82B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$11.48 Million
Adjusted EPS-$1.29
See more estimates
10-Day MA$65.01
50-Day MA$55.65
200-Day MA$81.37
See more pivots

Intellia Therapeutics Inc Stock, NASDAQ:NTLA

40 Erie Street, Suite 130, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.285.6200
Number of Employees: 485


Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.